| 摘要 |
<p>Efforts at treating a host of cancers have, separately, focused on antagonizing VEGF, a soluble ligand implicated in angiogenesis by binding to VEGF-receptor, and c-Met, a receptor tyrosine kinase that is mutated or differentially expressed in various tumors. Although these two targets are involved in different signaling pathways, the present inventors have surprisingly discovered that co-administration of specific-binding therapeutic proteins targeting VEGF and c-Met, respectively, has yielded a synergistic result in both in vitro and in vivo models, compared to administering these therapeutic proteins individually. The present invention, therefore, focuses on therapeutic methods resulting from this discovery and compositions for implementing the same.</p> |
